Slovakia Country Drug Report 2018

Drug-related research

The role of drug-related research and the use of research findings and best practices in the formulation and implementation of interventions are endorsed by the current national drug strategy.

Research is funded from the state budget, through the Ministry of Education, in the form of grants that either are intended for a specific research project or are provided to the research institution itself. In general, funds for research allocated from the state budget are limited and research is also supported by funding from the European Union. In 2015, the Slovak national focal point (NFP) to the EMCDDA allocated the majority of its annual state budget and EMCDDA grant to various studies. The main areas of research interest to the NFP were prevalence/incidence studies at national, regional and local levels; harms and infectious diseases, mortality, crime, harm reduction programmes and effectiveness; social reintegration programmes; effectiveness of prevention measures; public expenditures and social costs; new psychoactive substances (identification of substances and metabolites); health effects (hospital emergencies); trafficking and means of distribution; the drug market; prices; and the impact of legislative measures. Recent drug-related studies have focused on the prevalence of drug use, including wastewater analysis and responses to the drug situation.

The NFP maintains a database on studies in the drugs field, including bibliographic references, which is available on its website.

Drug-related research is conducted mainly by governmental agencies, university departments and hospitals, and also by the Slovak Academy of Sciences.

National scientific journals play an important role in disseminating drug-related research findings.

Slovakia main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.